Castle Biosciences, Inc. (CSTL) vs Harrow Health, Inc. (HROW)

A side-by-side comparison of Castle Biosciences, Inc. and Harrow Health, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CSTL vs HROW

growth of $100 · dividends reinvested · last 7y
CSTL +71.3% (+8.0%/yr)HROW +297.1% (+21.8%/yr)HROW compounded faster over this window
0200400600Start $100202120232025$171$397
CSTL HROW

CSTL vs HROW: by the numbers

  • •HROW is the larger company ($1.11B vs $1.04B market cap).
  • •Both run net losses; CSTL's is the smaller (-5.43% vs -13.51% net margin).
  • •CSTL grew revenue faster over the past five years (35.55% vs 34.52% CAGR).

Metrics side by side

Valuation

MetricCSTLHROW
P/S ratio2.924.04
P/B ratio2.2273.30
FCF yieldN/A0.48%

Profitability

MetricCSTLHROW
Gross margin77.26%73.28%
Operating margin-8.99%14.18%
Net margin-5.43%-13.51%
ROE-4.13%-244.91%
ROIC-6.33%1.81%

Growth (annualized)

MetricCSTLHROW
Revenue CAGR (5Y)35.55%34.52%
Total return CAGR (5Y)-10.28%27.66%

Frequently asked

Which has grown faster, CSTL or HROW?
Over the past five years, CSTL grew revenue faster — CSTL at a 35.55% CAGR versus HROW at 34.52%.
How have CSTL and HROW total returns compared?
Over the past 5 years, CSTL delivered -10.28% and HROW delivered 27.66% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.